December 6, 2016
Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform To Sienna’s Growing Pipeline
Westlake Village, Calif. (December 6, 2016) – Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced it has acquired Creabilis plc, a privately held specialty pharmaceutical company focused on developing first-in-class topical treatments for common inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus (itch). Under the terms of the agreement, Sienna will make an undisclosed upfront payment in cash and stock, as well as additional payments contingent upon achieving specific regulatory and commercial milestones, which could exceed $150 million in aggregate. Additional terms were not disclosed.
Sienna has acquired first-in-class late-stage and patented clinical candidates, including:
- A Phase IIb topical tropomyosin receptor kinase A (TrkA) inhibitor (SNA-120, formerly CT327) for the treatment of pruritus and psoriasis.
- A topical TrkA/janus kinase 3 (JAK3) inhibitor (SNA-125, formerly CT340) for the treatment of inflammatory skin conditions, including atopic dermatitis, psoriasis and pruritus.
These new drug candidates were generated through a proprietary “Topical by Design” platform technology developed by Creabilis that provides localized efficacy and limited systemic exposure. Sienna also acquired a portfolio of pre-clinical drug candidates generated by this technology.
The acquisition bolsters Sienna’s medical dermatology and aesthetics pipeline, which, in addition to several proprietary pre-clinical programs, includes a novel topical photoparticle therapy (SNA-001) in pivotal studies for the localized, non-systemic treatment of acne vulgaris and the permanent reduction of unwanted light-pigmented hair.
“The acquisition of Creabilis is transformative, expanding Sienna’s innovative and diversified pipeline,” said Sienna President and Chief Executive Officer Frederick C. Beddingfield III, M.D., Ph.D., who formerly developed leading dermatology and aesthetics brands such as BOTOX® Cosmetic, JUVÉDERM®, LATISSE®, KYBELLA®, ACZONE® and TAZORAC®. “Both the TrkA and TrkA/JAK3 programs offer the potential of highly differentiated topical treatments for inflammatory skin diseases and pruritus. Furthermore, the addition of the groundbreaking “Topical by Design” technology will allow Sienna to discover and develop innovative new drug candidates for areas of high unmet need in dermatology.”
Psoriasis is a common chronic inflammatory skin disease observed in about one to three percent of the general population. About 60 to 90 percent of patients with psoriasis suffer from pruritus (itch), one of the most distressing symptoms associated with the disease.2 Pruritus is also a common symptom in other inflammatory skin diseases, including atopic dermatitis. Currently there are no topical treatments approved by the U.S. Food and Drug Administration (FDA) specifically for pruritus.
Creabilis Chief Executive Officer Alex Leech said, “We have great confidence in the Creabilis platform and have been focused on ensuring these high-value assets progress through the clinic as expeditiously as possible. The management team at Sienna has a long and proven track record of successfully bringing innovative dermatology treatments to market, and we, together with our shareholders, believe that the portfolio is poised for success as part of Sienna’s medical dermatology pipeline.”
About Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc., is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Sienna is led by a team of accomplished scientists, clinicians and business leaders who have developed and commercialized leading global brands in dermatology and aesthetics. Sienna is building an innovative, diversified pipeline to address unmet needs in medical dermatology and aesthetics. The company’s investors include: ARCH Venture Partners; Partner Fund Management; Altitude Life Science Ventures; Venvest Capital; Two River; and several prominent medical dermatology and aesthetics industry luminaries. Find more information at www.siennabio.com.
About Creabilis plc
Creabilis is a specialty pharmaceutical company focusing on the development of novel topical treatments in the field of dermatology using their proprietary “Topical by Design” technology that creates first-in-class drugs specifically designed to provide localized efficacy while limiting systemic exposure. Creabilis is backed by highly respected life science investors including Sofinnova Partners, Neomed, and AbbVie Biotech Ventures Inc., and is led by an experienced management team. Creabilis’ corporate headquarters and development functions are based in the UK, with research activities in Italy.
BOTOX® Cosmetic, JUVÉDERM®, LATISSE®, KYBELLA®, ACZONE® and TAZORAC® are registered trademarks of Allergan, Inc.
John W. Smither
Chief Financial Officer
Investors and Media:
 Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA Kinase Inhibitor CT372 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015; 95: 542-548.
 Szepietowski JC, Reich A. Itch in Psoriasis Management. Curr Probl Dermatol. 2016; 50: 102-110.
Download PDF: Sienna-Creabilis Press Release